ES2528650T3 - Sistema terapéutico transdérmico que comprende buprenorfina - Google Patents

Sistema terapéutico transdérmico que comprende buprenorfina Download PDF

Info

Publication number
ES2528650T3
ES2528650T3 ES11784951.3T ES11784951T ES2528650T3 ES 2528650 T3 ES2528650 T3 ES 2528650T3 ES 11784951 T ES11784951 T ES 11784951T ES 2528650 T3 ES2528650 T3 ES 2528650T3
Authority
ES
Spain
Prior art keywords
weight
buprenorphine
composition
therapeutic system
transdermal therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11784951.3T
Other languages
English (en)
Inventor
Jens Fleschhut
Susanne Feinaeugle
Karin Lauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hexal AG
Original Assignee
Hexal AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43728780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2528650(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hexal AG filed Critical Hexal AG
Application granted granted Critical
Publication of ES2528650T3 publication Critical patent/ES2528650T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un sistema terapéutico transdérmico que comprende 1) una capa de soporte, 2) al menos una capa adhesiva que contiene fármaco que contiene una composición de aporte transdérmico de fármaco que comprende i. de 1 a 20% en peso de buprenorfina, basado en el peso total de la composición, ii. un componente adhesivo, que preferiblemente forma una masa amorfa, que comprende un polímero acrílico reticulado y un polímero acrílico no reticulado en una relación de 10 a 90 partes en peso a 90 a partes en peso, iii. y de 1 a 50% en peso de un mejorador de la penetración, basado en el peso total de la composición, que comprende un cetoácido, y 3) opcionalmente al menos una capa adhesiva adicional, y 4) también opcionalmente, una cubierta de separación.

Description

imagen1

Claims (1)

  1. imagen1
ES11784951.3T 2010-11-17 2011-11-17 Sistema terapéutico transdérmico que comprende buprenorfina Active ES2528650T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10014713 2010-11-17
EP10014713 2010-11-17
PCT/EP2011/005784 WO2012065740A1 (en) 2010-11-17 2011-11-17 Transdermal therapeutic system comprising buprenorphine

Publications (1)

Publication Number Publication Date
ES2528650T3 true ES2528650T3 (es) 2015-02-11

Family

ID=43728780

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11784951.3T Active ES2528650T3 (es) 2010-11-17 2011-11-17 Sistema terapéutico transdérmico que comprende buprenorfina

Country Status (9)

Country Link
US (2) US9844515B2 (es)
EP (1) EP2640389B1 (es)
CN (1) CN103200944B (es)
AU (1) AU2011331511C1 (es)
BR (1) BR112013012156A2 (es)
CA (1) CA2815898C (es)
DK (1) DK2640389T3 (es)
ES (1) ES2528650T3 (es)
WO (1) WO2012065740A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2882870C (en) * 2012-08-24 2020-12-15 Integurx Therapeutics, Llc Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014100599A1 (en) * 2012-12-21 2014-06-26 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014105480A1 (en) * 2012-12-28 2014-07-03 Teikoku Pharma Usa, Inc. Extended buprenorphine transdermal delivery compositions and methods for using the same
GB2529789A (en) * 2013-06-04 2016-03-02 Lohmann Therapie Syst Lts Transdermal Delivery system
US20160220507A1 (en) * 2013-07-10 2016-08-04 Jie Zhang Kit for sustained transdermal drug delivery using liquid or semisolid formulations and method of using the same
JP6188934B2 (ja) * 2013-10-07 2017-08-30 テイコク ファーマ ユーエスエー インコーポレーテッド デクスメデトミジン経皮組成物を含む疼痛管理用方法及び組成物
KR101881791B1 (ko) * 2013-10-07 2018-07-25 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물
KR101827980B1 (ko) 2013-10-07 2018-02-13 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
ES2847936T3 (es) 2013-10-07 2021-08-04 Teikoku Pharma Usa Inc Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina
KR101831290B1 (ko) * 2013-10-07 2018-02-22 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
DE102014013448A1 (de) 2014-09-16 2016-03-17 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales Therapeutisches System umfassend Buprenorphin
AR098771A1 (es) * 2014-12-16 2016-06-15 Amarin Tech S A Un dispositivo para la administración transdérmica de rotigotina
US9656441B2 (en) 2015-01-08 2017-05-23 Alfred E. Tiefenbacher ( Gmbh & Co. Kg) Transdermal patch
EP3067050A1 (en) * 2015-03-13 2016-09-14 Acino AG Transdermal therapeutic system with an overtape comprising two adhesive layers
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017048595A1 (en) * 2015-09-14 2017-03-23 Amneal Pharmaceuticals Llc Transdermal delivery system
AR102214A1 (es) * 2015-10-08 2017-02-15 Amarin Tech S A Un dispositivo para la administración transdermal de buprenorfina
WO2017172603A1 (en) * 2016-03-28 2017-10-05 Tioga Research, Inc. Topical formulation
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
EP3474831A1 (en) 2016-06-23 2019-05-01 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
CN109789106B (zh) 2016-07-27 2023-06-27 考里安有限责任公司 碳酸氢钠原位转化驱动胺药物的透皮递送
EP3558276A1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
DE102017112543A1 (de) * 2017-06-07 2018-12-13 Amw Gmbh Overtape für ein transdermales Darreichungssystem
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
WO2019126531A1 (en) 2017-12-20 2019-06-27 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
KR102255560B1 (ko) 2018-02-20 2021-05-24 주식회사 엘지화학 점착제 조성물 및 이를 포함하는 점착 필름
EP3764995A1 (en) * 2018-03-13 2021-01-20 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer
MX2020014286A (es) 2018-06-20 2021-03-25 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina.
MX2021000314A (es) * 2018-07-09 2021-03-25 Tyme Inc Formulaciones reductoras de tumores y metodos de uso de las mismas.
WO2021007584A1 (en) * 2019-07-11 2021-01-14 Henkel IP & Holding GmbH Acrylic polymer and adhesive compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939376C1 (es) * 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DE4301783C1 (de) 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
ES2164286T3 (es) 1993-04-20 2002-02-16 Hexal Ag Emplasto con sustancias activas.
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6344211B1 (en) * 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
LT2351555T (lt) 2004-02-23 2016-12-27 Euro-Celtique S.A. Piktnaudžiavimui atspari priemonė, skirta transderminiam opoido įvedimui
DE102004020463A1 (de) 2004-04-26 2005-11-10 Grünenthal GmbH Wirkstoffabgabesystem aus einem wirkstoffhaltigen Pflaster und mindestens einem Wirkstoffabgaberegulierungsmittel

Also Published As

Publication number Publication date
DK2640389T3 (en) 2015-03-09
US9844515B2 (en) 2017-12-19
EP2640389B1 (en) 2014-12-31
CA2815898A1 (en) 2012-05-24
AU2011331511C1 (en) 2018-01-18
US20180042861A1 (en) 2018-02-15
CN103200944A (zh) 2013-07-10
EP2640389A1 (en) 2013-09-25
CA2815898C (en) 2018-12-18
BR112013012156A2 (pt) 2017-12-05
CN103200944B (zh) 2016-05-04
AU2011331511B2 (en) 2016-04-07
AU2011331511A1 (en) 2013-05-30
US20130331803A1 (en) 2013-12-12
WO2012065740A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
ES2528650T3 (es) Sistema terapéutico transdérmico que comprende buprenorfina
CY1124764T1 (el) Υπογλωττια ανθεκτικα σε καταχρηση δισκια που περιεχουν βουπρενορφινη και ναλοξονη
EA201491164A1 (ru) Трансдермальная система доставки
PH12015502550A1 (en) Transdermal delivery system
CL2011003347A1 (es) Composicion farmaceutica que comprende un conjugado, correspondiente a benzoato de hidrocodona ; y uso en el tratamiento de una enfermedad, trastorno o afeccion mediada por la union de un opioide a receptores opioides.
BRPI0714712B8 (pt) dispositivo para administração de fármaco
AR097045A2 (es) Sistema terapéutico transdérmico
BR112015024271A2 (pt) sistema de fornecimento transdérmico
MY163809A (en) Transdermal drug delivery system containing donepezil
BRPI0915300C1 (pt) compostos de éster boronato e composições farmacêuticas dos mesmos
CY1116638T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας
EA201591124A1 (ru) Трансдермальная система доставки
RU2014125322A (ru) Средство и способ трансдермальной доставки эстрогена
CY1123398T1 (el) Συνθεση συνδυασμου
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
AR124497A2 (es) Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica
CY1110097T1 (el) Διπλοστοιβαδικο δισκιο για προληψη καρδιαγγειακων συμβαντων
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
CL2008001563A1 (es) Compuestos derivados de benzodioxanos condensados con heterociclos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, crisis de panico, entre otras.
CL2008000683A1 (es) Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de la enzima de conversion de angiotensina (ace); formulacion de dosis unitaria; y uso en el tratamiento de la diabetes.
WO2012111996A3 (ko) 갈란타민 또는 그의 염을 함유하는 경피흡수제제
EA201390980A1 (ru) Лекарственный пластырь для улучшенного трансдермального проникновения диклофенака диэтиламмония
EA201390246A1 (ru) Трансдермальные терапевтические системы с защитной пленкой, ингибирующей кристаллизацию (антиадгезионный материал)
AR082906A1 (es) Parches transdermicos de dosis baja con nivel elevado de liberacion de droga
TH152432A (th) องค์ประกอบแบบผสมผสาน